Actual usage and clinical effectiveness of insulin preparations in patients with Type 1 diabetes mellitus in Japan: CoDiC®-based analysis of clinical data obtained at multiple institutions (JDDM 3)

Diabetes Research and Clinical Practice

Volumn 72, Issue 3, 2006, Pages 277-283

  Kanatsuka, Azuma ^a   Kawai, Koichi ^b   Hirao, Koichi ^c   Oishi, Mariko ^d   Takagi, Hirofumi ^e   Kobayashi, Masashi ^f  

^a Chiba Central Medical Center   (Japan)

^b Kawai Clinic   (Japan)

^c HEC Science Clinic   (Japan)

^d Oishi Clinic   (Japan)

^e NIIGATA UNIVERSITY   (Japan)

^f UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Glycaemic control; Insulin preparation; Insulin treatment; Outcome research; Type 1 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; C PEPTIDE; GLYCOSYLATED HEMOGLOBIN; INSULIN DERIVATIVE;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DATA ANALYSIS; DATA ANALYSIS SOFTWARE; DATA COLLECTION METHOD; DISEASE COURSE; HEALTH SURVEY; HUMAN; INFORMATION PROCESSING; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; JAPAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; NON INSULIN DEPENDENT DIABETES MELLITUS;

ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; CROSS-SECTIONAL STUDIES; DATABASE MANAGEMENT SYSTEMS; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; JAPAN; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; TREATMENT OUTCOME;

EID: 33646593545     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2005.03.040     Document Type: Article

References (28)

1. The Expert Committee on the Diagnosis, Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabet. Care 20 (1997) 1183-1197
2. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15 (1998) 539-553
3. Committee of Japan Diabetes Society for the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee of Japan Diabetes Society on the Classification and Diagnosis of Diabetes Mellitus. Japan Diab. Soc. 42 (1999) 395-404 (in Japanese)
4. Lindholm A., McEwen J., and Riis A.P. Improved post-prandial glycemoc control with insulin aspart. Diabet. Care 22 (1999) 801-805
5. Ciszak E., Beals J.M., Frank B.H., Baker J.C., Carter N.D., and Smith G.D. Role of C-terminal β-chain residues in insulin assembly: the structure of hexameric LysB28 ProB29 human insulin. Structure 3 (1995) 615-622
6. Hermansen K., Colombo M., Storgaard H., OStergaard A., Kolendorf K., and Madsbad S. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabet. Care 25 (2002) 883-888
7. Kobayashi M., Yamazaki K., and Hayashi R. Diabetes campaign in Toyama prefecture and development of computerized diabetes care. Int. Diabet. Monitor (1999) 34-37
8. M. Kobayashi, K. Yamazaki, K. Hirao, M. Oishi, K. Kanatsuka, M. Yamauchi, et al., The status of diabetes control and anti-diabetic drug therapy in Japan - Across-sectional survey of 17,000 patients with diabetes mellitus (JDDM1), Diabet. Res. Clin. Pract., in press.
9. The Guideline for Epidemiology Study in Japan. The Ministry of Health, Labor and Welfare, June 30, 2003.
10. Zimmet P.Z., Tuomi T., Mackay I.R., Rowley M.J., Knowles W., Cohen M., et al. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet. Med. 11 (1994) 299-303
11. Kobayashi T., Maruyama T., Shimada A., Kasuga A., Kanatsuka A., Takei I., et al. Insulin intervention to preserve beta cells in slowly progressive insulin-dependent (Type 1) diabetes mellitus. Ann. New York Acad. Sci. 958 (2002) 117-130
12. Pieber T.R., Brunner G.A., Schnedl W.J., Schattenberg S., Kaufmannn P., and Krejes G.J. Evaluation of a structured outpatient group education program for intensive insulin therapy. Diabet. Care 18 (1995) 625-630
13. Berger M., and Muhlhauser I. Implementation of intensified insulin therapy: a European perspective. Diabet. Med. 12 (1995) 201-208
14. Howey D.C., Bowsher R.R., Brunelle R.L., and Woodworth J.R. [Lys(B28), Pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes 43 (1994) 396-402
15. Torlone E., Fanelli C., Rambotti A.M., Kassi G., Modarelli F., Di Vincenzo A., et al. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM. Diabetologia 37 (1994) 713-720
16. Heinemann L., Heise T., Wahl L.C., Trautmann M.E., Ampudia J., Starke A.A.R., et al. Prandial glycemia after carbohydrate-rich meal in Type 1 diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet. Med. 13 (1996) 625-629
17. Garg S.K., Carmain J.A., Braddy K.C., Anderson J.H., Vignati L., Jennings M.K., et al. Pre-meal insulin analogue insulin lispro vs. Humulin R insulin treatment in young subjects with Type 1 diabetes. Diabet. Med. 13 (1996) 47-52
18. Anderson J.H., Brunelle R.L., Koivisto V.A., Pfutzner A., Trautmann M.E., Vignati L., et al., The Multicenter Insulin Lispro Study Group. Reduction of postprandial hyperglycemia and frquency of hypoglycemia in IDDM patients on insulin analog treatment. Diabetes 46 (1997) 265-270
19. HollemanF, Schmitt H., Rottiers R., Rees A., Symanowski S., Anderson J.H., and The Benelux-UK Insulin Lispro Study Group. Reduce frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. Diabet. Care 20 (1997) 1827-1832
20. Ahmed A.B.E., and Home P.D. The effect of insulin analog lispro on night time blood glucose control in Type 1 diabetic patients. Diabet. Care 21 (1998) 32-37
21. Hermansen K., Fontaine P., Kukolja K.K., Peterkova V., Leth G., and Gall M.-A. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular insulin) in basal-bolus therapy for patients with Type 1 diabetes. Diabetologia 47 (2004) 622-629
22. Kwolewski A.S., Warram J.H., Rand L.I., and Kahn C.R. Epidemiologic approach to the etiology of type 1 diabetes mellitus and impaired glucose tolerance in adults. N. Engl. J. Med. 317 (1987) 1390-1398
23. Gorus F.K., and Belgian Diabetes Registry. Diabetes registries and early biological markers of insulin-dependent diabetes mellitus. Diabet. Metab. Rev. 4 (1997) 247-274
24. Pipeleers D., and Ling Z. Pancreatic β-cells in insulin-dependent diabetes. Diabet. Metab. Rev. 8 (1992) 209-227
25. Imagawa A., Hanafusa T., Miyagawa J., Matsuzawa Y., and The Osaka IDDM Study Group. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N. Engl. J. Med. 342 (2000) 301-307
26. Imagawa A., Hanafusa T., Uchigata Y., Kanatsuka A., Kawasaki E., Kobayashi T., et al. Fulminant type 1 diabetes. Diabet. Care 26 (2003) 2345-2352
27. The Diabetes Control and Complications Trial Research Group. The absence of glycemic threshhold for the development of long-term complications. Diabetes 45 (1996) 1289-1298
28. Pickup J., Mattock M., and Kerry S. Glycemic control with continuous subcutaneous insulin infusion compared with intensive insulin injection in patients with type 1 diabetes: meta-analysis of randomized, controlled trials. BMJ 324 (2002) 705